NeuroMab™ Anti-TNFR2 Antibody(NRP-0422-P778)

Figure 1 shows the results of replicate experiments performed to determine the effect of TNFRAB2 on T-reg cell proliferation.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.

Figure 2 is a graph showing the ability of TNFRAB1 and TNFRAB2 to generally inhibit T-reg cell proliferation.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.

Figure 3 is a graph showing the effect of TNFRAB1 and TNFRAB2 on T-reg cell proliferation relative to the effect induced by IL-2 treatment.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.

Figure 4 Flow cytometry plot showing various phenotypes of the effects of drugs directing T-reg cell growth (eg, TNFα, IL-2, and TNFR2 agonists) and the TNFR2 antagonist TNFRAB2 on T-reg cell proliferation.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.

Figure 5 is a graph showing the effect of TNFR2 antagonist antibodies on TNF[alpha] and lymphotoxin expression.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.

Figure 6 is a graph showing the effect of TNFR2 antagonist antibodies on FoxP3 and CD25 expression.

Treatment with a TNFR2 antagonist antibody preferentially inhibits the proliferation of CD25Hi-expressing T-reg cells. After incubation for up to 48 h with IL-2 (200 U/ml), TNFα (20 ng/ml), or TNFR2 antagonist antibody (12.5 pg/ml) alone, the proportion of CD4+, CD25Hi+ cells expressing TNFR2 is shown.